Cited in boardrooms, legal proceedings & government briefings since 2017

The North American Cannabis Report: 3rd Edition provides the latest information and analysis on the development of the nascent cannabis markets across North America.
Cited in boardrooms, legal proceedings & government briefings since 2017. Our figures are built to be defended — sourced, modelled and signed off by PP’s analysts.
Trusted by teams at
The North American Cannabis Report: 3rd Edition provides the latest information and analysis on the development of the nascent cannabis markets across North America. It combines PP’s proprietary market sizing with regulatory analysis, giving investors and corporates a single, citable reference — delivered digitally, licensed for internal use, and backed by the analysts who built the numbers.
PDF + data
delivery format
2022
published
In 2021, the North American cannabis industry continued to grow and showed more promise than ever, with New York, New Jersey, Virginia, New Mexico, Montana and Connecticut all enacting, amending or passing adult-use cannabis legislation during the year. This state-by-state approach to legalising adult-use cannabis has especially benefited America’s larger multi-state operators, who are gradually expanding into emerging state markets, acquiring licences and establishing cultivation facilities and distribution channels as new laws are implemented. Despite a wealth of optimism for full cannabis legalisation in the United States after President Joe Biden was elected and the Democrats took control of the Senate, there has been very little movement by both House Representatives and Senators to pass new laws that would create a clearer path for the industry. Prohibitions Partners has combined all of this opportunity with current consumer behaviours and anticipated legislation on both the adult-use and medical sides to create sales projections from 2022 to 2026. In the US, adult-use sales are estimated to reach US$18.5 billion in 2022 and grow by 218% to US$58.8 billion by 2026. As adult-use markets grow, they will eat into medical markets. With that in mind, estimated sales will grow by 41.5% between 2022 and 2026, from US$9.2 billion to US$13.1 billion. Canadian adult-use sales are estimated to experience healthy growth as well, from just over US$4 billion in 2021 to US$7.6 billion in 2026, or by 91%. The federal adult-use programme will flatten medical sales, however, which are expected to decrease by 11%, from US$440 million to US$379 million.
Investors & analysts
Defensible sizing and forecasts to underwrite the thesis.
Corporate strategy & FMCG
Opportunity sizing and entry routes across key markets.